GLP1R and COVID-19: The meta‐analysis of the nine studies9, 10, 11, 12, 13, 14, 15, 16, 17 revealed significant reduction in the odds of mortality with preadmission/prediagnosis use of GLP‐1 receptor agonists relative to non‐use of GLP‐1 receptor agonists in COVID‐19 patients with diabetes.